Sometimes a strain develops that, while not entirely new, is new enough to spread more efficiently because it is not well ...

Pertuzumab-dpzb is now considered an interchangeable biosimilar to pertuzumab as part of treatment combinations in multiple ...

Somatic mutations with effects similar to those seen with VEXAS syndrome are increasingly seen as possible drivers of ...

A trial finds a liberal vs restrictive transfusion threshold for at-risk cardiac patients may improve heart failure and ...

Karina Volkova trains in a clinic using a temporary permit that expires in 2027, giving her a narrow window to clear all ...

An analysis of a German multicentre study reveals that women are more likely than men to receive inappropriate diagnostic ...

A new opinion paper shows no convincing evidence that there is a causal link between gut bacteria and autism, citing weak ...

The regulator backed the medicine after phase 3 data showed dramatic reductions in HAE attacks and sustained disease control ...

Social media is accelerating the spread of misleading health information, and public health experts say rebuilding trust will ...

Weight loss at the time of GLP-1 discontinuation was 10.1% overall, 9.7% for those with T2D, and 11.1% for those without.

The recommendation follows results showing markedly longer time to diagnosis of stage 3 T1D in treated patients, a condition ...

The EMA’s recommendation follows evidence that the targeted therapy improves progression-free survival in patients whose ...